Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Melanoma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Melanoma
    TopAbstracts in Melanoma 11/19/2008 - (DGNews)
    TopAbstracts in Melanoma 10/22/2008 - (DGNews)
    Methyl Aminolevulinate Photodynamic Therapy an Alternative to Surgery for Superficial Basal-Cell Carcinoma: Presented at EADV - (DGDispatch)
    TopAbstracts in Melanoma 09/24/2008 - (DGNews)
    Chest X-ray Prior to Sentinel Lymph Node Biopsy May Not Be Useful in Initial Staging of Primary Melanoma: Presented at ESSO - (DGDispatch)

    News archive

     Recent webcasts/CME - Melanoma

    Webcasts/CME archive

     Recent cases - Melanoma
      A 90-Year-Old Woman with an Asymptomatic Spot on Her Cheek
      Primary Malignant Melanoma of the Esophagus With Separate Foci of Melanoma In Situ and Atypical Melanocytic Hyperplasia in a Patient Positive for Human Immunodeficiency Virus: A Case Report and Review of the Literature
      Primary Malignant Melanoma of the Lower Oesophagus Presenting with Dysphagia and Upper Gastrointestinal Bleeding: A Case Report
      Cardiovascular Magnetic Resonance of the Charcoal Heart
      Ring Melanoma of the Ciliary Body: Clinical and Ultrasound Biomicroscopic Characteristics

      Cases archive
        




      my personal edition > melanoma > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Interferon Alpha Boosts Temozolomides's Efficacy in Metastatic Melanoma: Presented at ASCO

      By Rabiya S. Tuma

      CHICAGO, IL -- June 3, 2003 -- Temozolomide in combination with interferon alpha significantly increases response rates in patients with metastatic melanoma, although the combination increases the frequency of grade 3/4 haematological toxicity.

      Although temozolomide monotherapy has been proven effective for treatment of melanoma, researchers have not tested its efficacy in combination with other drugs. The Dermatologic Cooperative Oncology Group (DeCOG) designed an international, randomised, phase III trial to compare the safety and efficacy of temozolomide as a single agent and in combination with interferon alpha.

      The findings from this study were presented here May 31st at the 39th Annual Meeting of the American Society of Clinical Oncology.

      A total of 294 patients enrolled in the ongoing study between December 1998 and January 2002. Inclusion criteria required the patients have metastatic melanoma stage M1 with no prior chemotherapy, no brain metastases, and a life expectancy of greater than 3 months.

      Of 280 evaluable patients, 138 are being treated with the single agent and 142 with the combination. Patients treated with temozolomide alone receive 200 mg/m2 on days 1 to 5 on a 4-week cycle, while those treated with the combination therapy receive the same regimen of temozolomide in addition to 5 MU/m2 interferon on days 1 to 5 every 4 weeks.

      In the single-agent arm, 2.2% of patients had a complete response and 11.6% had a partial response, compared with 8.5% and 15.5%, respectively, in the combination arm. Additionally, 24.6% and 17.6% had stable disease in the single and combination arms, respectively. This was a statistically significant difference in response rates, according to the researchers.

      At analysis, however, the median overall survival was 7 months for patients in both arms.

      The patients in the combination therapy arm had more frequent grade 3/4 haematological complications -- 34% compared with 9.6% in the monotherapy arm.

      Based on these interim data, the researchers concluded that the objective response rate is significantly higher with the combination therapy but that there is not yet evidence for prolonged survival.


      [Study title: Temozolomide in Combination With Interferon Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized Phase III Multicenter Study of the Dermatologic Cooperative Oncology Group (DeCOG). Abstract 2887]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send